STHLM3 - Prostate Cancer Diagnostic Trial

Karolinska Institute

Status: Completed

Conditions: Prostate Cancer

Treatments: Diagnostic Test: STHLM3

Study type: Interventional

Funder types: Other

Identifiers

NCT03639649

Karolinska1

Details and patient eligibility

About

STHLM3 is a paired diagnostic trial aiming to assess whether a panel of biomarkers for prostate cancer can substantially reduce the proportion of men referred to biopsy whilst maintaining sensitivity for aggressive prostate cancer

Enrollment: 58,818 patients

Sex: Male

Ages: 50 to 69 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Age 50-69
• Residential address in Stockholm County

Exclusion criteria

• Previous Prostate Cancer Diagnosis
• Not able to comprehend inform consent material

Trial design

Primary purpose: Diagnostic

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: Quadruple Blind

---

58,818 participants in 2 patient groups

STHLM3

Experimental group

Treatment:

Diagnostic Test: STHLM3

PSA

Active Comparator group

Treatment:

Diagnostic Test: STHLM3